Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's lymphoma: a systematic review and economic evaluation

Health Technol Assess. 2002;6(3):1-85. doi: 10.3310/hta6030.

Authors

B Wake¹, C Hyde, S Bryan, P Barton, F Song, A Fry-Smith, C Davenport

Affiliation

¹ Department of Public Health and Epidemiology, University of Birmingham, UK.

PMID: 12022936
DOI: 10.3310/hta6030

No abstract available

Publication types

Review
Systematic Review

MeSH terms

Antibodies, Monoclonal / economics
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Agents / economics
Antineoplastic Agents / therapeutic use*
Cost-Benefit Analysis
Drug Costs
Drug Resistance, Neoplasm
Humans
Lymphoma, Follicular / drug therapy*
Lymphoma, Follicular / epidemiology
Lymphoma, Follicular / pathology
Neoplasm Recurrence, Local / drug therapy*
Neoplasm Recurrence, Local / epidemiology
Neoplasm Recurrence, Local / pathology
Neoplasm Staging
Patient Compliance
Randomized Controlled Trials as Topic
Research / trends
Rituximab
Survival Analysis
Technology Assessment, Biomedical
Treatment Outcome
United Kingdom / epidemiology

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Agents
Rituximab